This is a new solid piece of evidence: despite common belief genetic breast cancers are not clinically different from non-genetic counterparts if share similar clinico-pathologic characteristics (i.e when analysis is adjusted to known confounding factors such as age, stage, etc).
Article Breast Cancer Prognosis in BRCA1 and BRCA2 Mutation Carriers...
Just looking at the cohort, is very interesting: " Ninety-three had BRCA1 mutations; 71, BRCA2 mutations; one, both mutations; 1,550, sporadic breast cancer; and 1,505, familial breast cancer"
These numbers speak for themselves. There is a 50:50 chance of occurrence of breast cancer from "sporadic" events !! BRCA-mutations account for so few....
And now this study, like others, show that the odds of dying from breast cancer whatever the cause, EVEN after "After adjustment for age, tumor stage and grade, nodal status, hormone receptors, and year of diagnosis" is roughly the same. Remarkable.
BUT, I must ask what adjustment has been made for treatment modalities. This would be interesting also.
Here is cohort definition: "one, BRCA1 mutation carriers if a deleterious mutation in BRCA1 was identified; two, BRCA2 mutation carriers if a deleterious mutation in BRCA2 was identified; three, other familial breast cancer if there was a reported history of breast and/or ovarian cancer in a first- or second-degree relative at diagnosis in the absence of a known BRCA mutation; and four, sporadic breast cancer (all others)"
- Badges
- Science method